Navigation Links
Researchers find significant increase in painkillers prescribed to US adults in the ER
Date:3/14/2014

WASHINGTON (March 14, 2014) George Washington University (GW) researchers report dramatic increases in prescriptions of opioid analgesics, such as Percocet, Vicodin, oxycodone and Dilaudid, during U.S. emergency department visits from 2001 to 2010. These findings were not explained by higher visit rates for painful conditions, which only increased modestly during the time period. This report was published today in the journal Academic Emergency Medicine.

"This trend is especially concerning given dramatic increases in opioid-related overdoses and fatalities in recent years," said Maryann Mazer-Amirshahi, M.D., co-author of the study and adjunct instructor of emergency medicine at the GW School of Medicine and Health Sciences (SMHS). "Using prescription opioids to treat acute painful conditions in emergency departments and hospitals might do more harm than good, as they can potentially lead to misuse and addiction. More needs to be done to monitor opioid prescriptions in emergency departments having recommended standard approaches may be a good starting point."

Mazer-Amirshahi and colleagues found that between 2001 and 2010, the percentage of overall emergency department visits where an opioid analgesic was prescribed increased from 20.8 percent to 31 percent. For some opioids, prescription rates increased dramatically; Dilaudid, one of the most potent yet addictive medications, went up 668.2 percent. The percentage of visits for painful conditions during the period only increased by four percent, from 47.1 percent in 2001 to 51.1 percent in 2010.

"Emergency department providers are often caught in a difficult position because some have their pay incentivized based on how patients report their satisfaction with their experience. The intention is always to provide appropriate pain relief, but many patients have come to expect opioids," said Jesse Pines, M.D., co-author of the study and director of the Office of Clinical Practice Innovation at GW SMHS. "When patients in pain want opioids, but don't get them which is common they may report a poor experience. We need to carefully consider how to balance these issues when it comes to national policy, particularly local and national payment policies, in this country."

The study analyzed data from the National Hospital Ambulatory Medical Care Survey, exploring which demographic groups, medications, and reasons for visiting the emergency room may account for this change in prescribing rates. In their analysis, the authors found the following over the ten-year study period:

  • Opioid prescribing increases across all age groups, including those over 65 years

  • Increases in opioid use in both blacks and whites; however, blacks were consistently prescribed fewer opioids than whites

  • Significant increases in opioid use in all categories of payer

  • Largest proportional increase in opioid prescriptions in Midwestern states; Highest overall frequency of opioids prescribed in Western states; Lowest rates of opioid utilization in Northeast states

  • Opioids more commonly prescribed in urban emergency departments and in nonprofit hospitals

  • Increases in prescription rates for all opioid analgesics, except codeine and meperidine

  • Greatest relative increases in use of hydromorphone (known as Dilaudid) and morphine; Hydromorphone and oxycodone had the greatest relative increases from 2005-2010


'/>"/>

Contact: Lisa Anderson
lisama2@gwu.edu
202-994-3121
George Washington University
Source:Eurekalert

Related medicine news :

1. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
2. Researchers destroy cancer with cryoablation & nanoparticle-encapsulated anticancer drug
3. NYU researchers find majority of Latinas are unaware of their risk of diabetes
4. UF researchers find drug therapy that could eventually reverse memory decline in seniors
5. Researchers identify carbohydrates in a coal mine for cancer detection
6. Researchers X-ray living cancer cells
7. Fox Chase researchers discover new mechanism of gene regulation
8. Penn researchers show nuclear stiffness keeps stem cells and cancer cells in place
9. CWRU researchers find byproducts of bacteria-causing gum disease incite oral cancer growth
10. Researchers make the invisible visible
11. Researchers look for culprit behind oral health problems in HIV-positive patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: